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ABSTRACT 
GINGRAS, SEBASTIEN Association of Glucocorticoid Receptor 
Polymorphisms with Metabolic Characteristics and Bariatric Surgery in Bariatric 
Patients. Department of Biological Sciences, June 2016. 
ADVISOR: Dr. Brian D. Cohen 
Cortisol acts on target tissues through the glucocorticoid receptor (GR). When in 
high concentration in the blood, it causes an obesity phenotype with hyperglycemia, 
hyperglyceridemia, hypertension and weight gain, known as Cushings’ Syndrome or 
Disease (CS/D). Hypersensitivity-causing single-nucleotide polymorphisms (SNPs) of 
the GR have been shown to lead to a similar phenotype. Because of the symptomatic 
resemblance between CS/D and Metabolic Syndrome (MS), we and others hypothesized 
that the MS may be a Cushingoid-like state with absence of hypercortisolemia, but with 
GR hypersensitivity. Additionally, the link between GR SNPs and the success of bariatric 
surgery as measured by the percent of excess body weight loss (%EBWL) following 
bariatric surgery has been largely left untested.  
We tested 62 obese bariatric patients and 51 normal weight college students for 
the presence of the BclI and N363S SNPs using a polymerase chain reaction technique 
with allele-specific primers. We first compared the prevalence of the SNPs in our 
populations and found them to be higher in the obese population for both SNPs. We also 
obtained a variety of metabolic parameters on the bariatric population and looked for 
significant differences across genotypes using one-way ANOVAs. Homozygous mutants 
for the BclI SNP showed a significant difference in triglyceride levels from 
heterozygotes. While all other parameters were non-significant, BclI mutants tended to 
have higher LDL cholesterol levels and lower HDL cholesterol levels with only slightly 
higher BMI, and N363S heterozygotes seemed to have higher LDL levels, systolic BP 
and blood glucose than homozygous wild-types. Our only BclI-positive/N363S-positive 
patient also tended to have higher blood glucose, LDL cholesterol, and systolic blood 
pressure, when compared to BclI-positive/N363S-negative patients. Finally, BclI-positive 
patients who underwent a gastric band tended to lose less weight following bariatric 
surgery than patients on whom other weight-loss surgeries were performed. 
Taken together, these results support the hypothesis that GR SNPs have a 
significant impact on metabolic profiles, suggesting that GR SNPs could contribute to the 
development of disease states such as the MS, and affect the success of gastric band 
surgery.
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INTRODUCTION 
Cortisol and the HPA Axis 
Cortisol is one of the most versatile hormones in the human body. It belongs to a 
group of steroid hormones called glucocorticoids that have a wide variety of effects on 
human peripheral tissues, mainly in response to physiological and psychological stress1. 
Glucocorticoids mediate inflammation by causing immune system suppression, and are 
involved in mood maintenance and cognitive processes1. They also play a part in 
regulating circadian rhythms1. Some evidence even suggests that they modulate the 
process of programmed cell death - or apoptosis2-4. More importantly, they are essential 
to the maintenance of energy homeostasis by regulating glucose, fat and protein 
metabolism1. By acting through its receptor, cortisol is an essential hormone involved in 
the catabolism of lipids and carbohydrates from peripheral tissues such as adipose 
tissues1. It acts on the liver to promote gluconeogenesis, the synthesis of glucose from 
smaller derivatives, and glycogenolysis, the breakdown of glycogen into glucose5. It also 
increases the synthesis of LDL and free fatty acids, and enhances the activity of lipase, 
the enzyme that catalyzes the breakdown of lipids into fatty acids, resulting in elevated 
triglycerides and LDL cholesterol levels5. Finally, it causes insulin resistance, which also 
contributes to increased lipid levels5. For these reasons, glucocorticoids and their effects 
on the body represent an intriguing area of study in the field of obesity. 
In humans, cortisol is the primary glucocorticoid. It is produced by the adrenal 
glands following activation of the hypothalamic-pituitary-adrenal (HPA) axis by stressors 
(Figure 1)6. Stress causes the release of corticotropin-releasing factor (CRH) from the 
hypothalamus, and this hormone acts on the corticotrophs of anterior pituitary to produce 
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Figure 13. The components of the HPA axis. 
The HPA axis contains negative feedback 
loops typical of the endocrine system. It 
culminates in the production of 
glucocorticoids, which are essential for many 
organs and systems. 
adrenocorticotropic hormone (ACTH) 6. ACTH 
binds to receptors on the cortex of the adrenal 
glands, and initiates the production of 
glucocorticoids and sex hormones in the zona 
fasciculata and zona reticularis, respectively6.  
Cortisol is derived primarily from the metabolism 
of cholesterol, which can be synthesized de novo, 
but is obtained mostly through an individual’s 
diet7. Cholesterol, normally stored in lipid vesicles 
as an ester, is hydrolyzed into free cholesterol and 
transported to the mitochondria where it is 
converted to pregnenolone in the rate-determining step of steroidogenesis7. Then, 
enzymes in the mitochondria and endoplasmic reticulum catalyze the conversion of 
pregnenolone into a variety of steroid intermediates, and finally into steroid hormones 
such as cortisol (Figure 2)7. The enzymes present in a particular tissue, thus, determine 
which steroid hormone is likely produced and secreted by that tissue.  
Figure 234. Steroidogenesis. Important for our purposes are the 
intermediates and enzymes required for the conversion of cholesterol to 
cortisol. 
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Figure 31. The interactions of the cortisol-bound GR with 
other cellular components in target tissues. This very 
simplified schematic attempts to depict the complexity of GR 
function in human peripheral cells. 
In response to ACTH, cells 
in the zona fasciculata of the 
adrenal cortex increase cholesterol 
mobilization and transport into the 
mitochondria, which leads to the 
production of cortisol7. Once 
synthesized, cortisol is released 
into the circulation mostly bound 
to corticosteroid binding globulins, 
and is delivered to a variety of 
target tissues8. Because of their properties, steroid hormones must constantly be produced 
and released to maintain adequate levels in the blood, and usually produce slower and 
more sustained responses7. To respond to cortisol, a tissue must have a receptor that 
responds to the hormone (Figure 3)9. In most cases, cortisol exerts its effects by binding 
the glucocorticoid receptor (GR), which is present in most cells of the body1. 
Interestingly, when high levels of cortisol are in the blood, cortisol can function as a 
mineralocorticoid and bind to the mineralocorticoid receptor, causing the effects 
normally associated with mineralocorticoids3.  
Cortisol’s impact on tissues is also controlled peripherally by 11β-HSD I, which 
converts the inactive cortisone to cortisol, its active form, and 11β-HSD 2, which 
catalyzes the reverse reaction10. Research suggests that the tissue-specific functions of 
these two enzymes may differ between obese and normal weight individuals10. 
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Figure 435,36. Ribbon structures of the GR. 
A: Cortisol-bound ligand-binding domain, 
B: DNA-binding domain 
A 
B 
Finally, as is commonly seen in the endocrine system, cortisol suppresses CRH 
production in the hypothalamus and ACTH production in the anterior pituitary in a 
negative feedback fashion (Figure 1)11. 
Glucocorticoid Receptor Structure and Function 
The GR is part of the nuclear hormone 
superfamily, whose members are characterized 
by their similar structure and their ability to bind 
DNA to alter gene expression12. The GR 
receptor is highly polymorphic and the unique 
gene encoding it gives rise to drastically 
different variants of the receptor13. Structurally, 
the receptor consists of three major domains: a 
250 amino acid carboxyl terminal ligand-binding 
domain, a central 60 to 70 amino acid DNA-
binding domain, and a variable amino terminal 
transactivation domain (Figure 4)1,13.  
In the classical model, cortisol binds to the ligand-binding region of the GR in the 
cytosol, causing a conformational change in the protein that allows it to enter the nucleus, 
bind DNA through its DNA-binding domain, and act as a transcriptional switch that turns 
genes on and off (Figure 3)13. However, more recent studies highlight the complexity of 
the intracellular and intranuclear interactions of the GR. They suggest that, once bound 
by a ligand, the many different isoforms of the GR interact with a variety of cytosolic 
5 
 
Figure 511. Generation of the 
different isoforms of the GR that 
give rise to its huge functional 
diversity. Contributing to this 
diversity are isoforms due to A: 
the 3 promoter sequences 
modulating the 9 exons of the 
unique GR gene, B: alternative 
splicing of the transcripts, C: 
variable translation start 
locations and D: post-
translational modifications. 
molecules such as chaperones, kinases, phosphatases, nuclear shuttling proteins and the 
proteasome, in addition to numerous transcription factors and coactivators (Figure 3)1,13.  
The GR is encoded by only one gene, the NR3C1 gene, located on chromosome 
5q11-q13, a puzzling fact given its highly diverse functions1,13. Figure 5 describes how 
such a wide variety of functions are made possible. First, as depicted in 5A, gene 
expression is controlled by 3 promoter regions that have the ability to recruit unique 
combinations of transcription factors, and that lead to the transcription of different parts 
of the GR gene13. This process gives rise to alternative transcripts that are believed to 
vary depending on the cell type and the environmental conditions, and account for some 
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of the huge diversity in GR expression13. In addition, as shown in 5B, these alternative 
transcripts can undergo alternative splicing, which increases the diversity of messenger 
RNAs even further. Evidence also suggests that translation initiation may begin at 
different locations on the messenger RNA, forming translational isoforms that have 
different biochemical properties, as is portrayed in 5C13. Finally, segment 5D shows that 
the GR can be modified by other intracellular proteins such as kinases and phosphatases 
following translation13. All of these mechanisms permit the creation of a large database of 
GRs that differ in function and interact intricately with the environment to produce a 
wide variety of effects on the body. 
The importance of the GR for life was highlighted in mice with GR-knockouts; 
they have been shown to die only a few minutes following birth due to lung collapse 
caused by uncontrolled inflammation of the lungs3. 
Glucocorticoid Receptor Single-Nucleotide Polymorphisms 
The many isoforms of the GR, which serve integral functions in the human body, 
originate from a single gene, causing the GR to be strongly affected by mutations in the 
gene that codes for it. A wide range of single-nucleotide polymorphisms (SNPs) of the 
Figure 68. The main SNPs of the GR. The N363S SNP is located in exon 2, and the BclI is intronic. While 
some polymorphisms cause GR hypersensitivity, others cause resistance of the GR. 
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Figure 78. Clinical effects of hypersensitivity-causing and 
resistance-causing SNPs of the GR. 
GR gene have been reported, some of which are thought to cause altered lipid and 
carbohydrate profiles.  
Yet, because of the many different functions of the GR, the phenotypic impact of 
SNPs at the organismal level has been difficult to describe accurately. In fact, while the 
research literature on SNPs is extensive, conclusive results remain to be obtained, in 
some part due to inconsistencies in the size, age, gender and race/ethnicities of sample 
populations10. While some SNPs have 
been associated with GR resistance, 
others have been shown to cause 
hypersensitivity of the GR to 
glucocorticoids11. Two SNPs that fall 
into the latter category are the BclI and 
the N363S11. 
The BclI polymorphism consists of a C  G nucleotide change in the intron 
downstream of exon number two, 646 nucleotides away from the exon-intron junction10. 
It is estimated that 38.0% of the population are positive for the G allele1. The first 
analysis of the impact of the BclI SNP on metabolic parameters was performed by 
Weaver et al. (1992), and found no difference in the prevalence of the mutant allele 
between obese and non-obese populations of premenopausal women, although it did find 
that the obese individuals had higher insulin levels and were more insulin resistant than 
the non-obese individuals10. Some subsequent studies have found increased body mass 
index (BMI), waist-to-hip ratio (WHR) and abdominal obesity in the G-allele carriers, but 
others have shown no such associations11. The BclI SNP has also been linked to higher 
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risk of hypertension, but once again, no correlation has been found between the presence 
of the mutant allele and BP, triglycerides or blood glucose in replicate studies using 
different populations11. The only parameter on which the evidence seems to agree is total 
cholesterol, which is believed to be higher in BclI carriers11.  
On the other hand, the N363S polymorphism is an AAT  AGT change in codon 
363 of exon 2 of the GR gene.10 Its prevalence is significantly lower than the BclI SNP at 
about 3.5% of the population1. Just like for the BclI SNP, the findings regarding the 
N363S SNP are mixed. Some research suggests an association with BMI and WHR, but 
these results haven’t been successfully replicated by other groups11. However, there is 
strong evidence for a correlation between the presence of the N363S allele and higher 
serum triglycerides and LDL cholesterol levels11. 
The mechanisms by which the BclI and N363S SNPs cause glucocorticoid 
hypersensitivity are still unknown, though some theories are presently being 
investigated11. 
Cushing’s Syndrome/Disease and the Metabolic Syndrome 
Because of cortisol’s importance in lipid and carbohydrate homeostasis, it is not 
surprising that alterations in the HPA pathway can cause serious metabolic dysfunctions, 
such as are seen in Cushing’s Syndrome or Disease (CS/D)14. CS/D is characterized by 
hypercortisolemia, which can be caused by deficiencies in many components along the 
HPA axis14. Its clinical presentation is extremely varied, but has many commonalities 
with symptoms associated with obesity such as dyslipidemia, hypertension, glucose 
intolerance, and increased visceral adiposity14,15. 
9 
 
The rapidly increasing prevalence of obesity in our society has caused a related 
increase in obesity-related symptoms such as abdominal adiposity, insulin resistance, 
dyslipidemia, elevated BP, and prothrombotic and proinflammatory states, a cluster of 
symptoms that is diagnosed as the Metabolic Syndrome (MS)16. Yet, a biologically-
based, mechanistic explanation for the MS has yet to be formulated17.  
Meanwhile, with this debate still ongoing, clinical cases of patients with low or 
normal cortisol presenting with symptoms of CS/D have begun to appear. In 1990, Iida et 
al. presented the first case of a patient with Cushing-like symptoms and 
hypocortisolemia18. They found no abnormality in the HPA axis or cause for his 
hypocortisolemia, and the patient’s skin fibroblasts were shown to be hyperreactive to 
glucocorticoids in vitro18. The researchers thus suggested that the hypocortisolemia may 
have been caused by a hypersensitivity of peripheral tissues to cortisol18. Al-Shoumer et 
al. (2008) reported the case of a 32 years old woman with similar characteristics19. This 
has led some groups to suggest that the MS may be a Cushingoid-like state with normal 
cortisol levels, but with hypersensitivity of the GR. 
Bariatric Surgery 
The obesity epidemic has led to a rise in prominence of bariatric surgery in the 
treatment of morbid obesity20. There are three main types of bariatric surgery, most of 
which are now performed laparoscopically: the Roux-en-Y gastric bypass, the sleeve 
gastrectomy and the adjustable gastric band. A large body of evidence suggest that 
bariatric surgery causes large changes in endocrine pathways, such as the HPA axis, that 
mediate weight loss and target comorbidities such as type 2 diabetes, hypertension, 
hyperlipidemia, heart disease and depression20,21. For example, the Roux-en-Y has been 
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shown to greatly reduce the development of type 2 diabetes in a majority of patients21. 
More specifically, massive weight loss, such as is associated with bariatric surgery, has 
been shown to decrease insulin resistance in adipose tissue, lower cortisol secretion rates, 
and reduce glucocorticoid production through inhibition of key steroidogenic enzymes22. 
Yet, perhaps surprisingly, only one study to date has looked at how genetic markers 
correlate with bariatric surgery success as measured by weight loss or regain, and none 
have targeted GR SNPs specifically23. Nevertheless, GR SNPs’ effects on metabolic 
parameters make them likely candidates for the genetic susceptibility of some individuals 
to reduced weight loss or increased weight regain following bariatric surgery.  
The purpose of our studies is thus threefold: first, we wish to evaluate the 
prevalence of the BclI and N363S hypersensitivity-causing SNPs in an obese, post-
bariatric population as compared to a normal weight population of college students. 
Second, we are interested in how the presence of these SNPs correlates with metabolic 
parameters, specifically BMI, blood glucose levels, serum triglycerides, HDL and LDL 
cholesterol levels, and systolic and diastolic BP. This could support a mechanism for the 
development of the MS in which hypersensitivity of the GR plays an important role. 
Thirdly, given the importance of the HPA axis in weight management, we want to look at 
how the presence of SNPs correlates with success of bariatric surgery as measured by 
percent of excess body weight loss (%EBWL) following surgery. These findings could 
guide decisions to undergo invasive weight loss surgery and improve the care of 
morbidly obese individuals.   
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METHODS 
 
DNA Collection 
The buccal cheek cells of 62 patients at Ellis Bariatric Care Center in Niskayuna, 
NY, and of 51 undergraduate students at Union College in Schenectady, NY, were 
collected. Approval to collect bariatric patient samples was obtained from Ellis Hospital’s 
Institutional Review Board (Appendix, Section A), and the Union College Human 
Subjects Review Committee granted us approval to collect student samples (Appendix, 
Section B). The purpose of the study and the rights of the participants were explained, 
and informed consent was obtained prior to saliva collection for both groups (Appendix, 
Section C). The participant poured 10 mL of 0.1% saline solution contained in a 15 mL 
centrifuge tube in his or her mouth, swished it around for 30 seconds, and spat the saline 
in a plastic cup. The content of the cup was then manually transferred back to the 15 mL 
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centrifuge tube to limit the amount of saliva lost in the procedure. The tubes were then 
labelled with the participant’s medical record number (MRN), and stored at 4⁰C before 
DNA extraction. 
DNA Isolation 
The DNA was isolated using Chelex 100 beads by Bio-Rad©. See Appendix, 
Section C for a detailed protocol. 
PCR Using Allele-Specific Primers 
Because of inconsistent early trials, purified DNA concentration was quantified 
using a Nanodrop© prior to the PCR procedure. Our inquiries being solely qualitative, 
the goal was simply for the template concentration in the PCR tube to be high enough for 
the PCR reaction to be successful. Thus, the concentration value obtained using the 
Nanodrop© guided our evaluation of the amount of template used for the PCR reaction 
(Table 1). 
Table 1. Amount of Template Used for PCR reactions Based on Original 
Concentration of BclI and N363S samples 
 BclI N363S 
Below 20 ng/µL 30 µL 25 µL 
Between 20-30 ng/µL 25 µL 22.5 µL 
Above 30 µL 20 µL 20 µL 
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Every PCR tube used in the PCR reactions contained a total volume of 50 µL.  
Table 2. Reagent Quantity in a Typical PCR Tube  
Reagent Quantity 
1) Deionized Water 50 µL – (2+3+4+5+6+7) 
2) Buffer 5 µL 
3) dNTPs 1 µL 
4) Common Primer 1 µL 
5) DNA polymerase 0.5 µL 
6) WT or MUT Primer 1 µL 
7) Patient Template Amount based on Table 1 
 
Based on known DNA sequences, wild-type (WT) primers were specifically designed to 
bind only the common GR gene sequence at the BclI and the N363S sites, respectively. 
In contrast, mutant (MUT) primers were designed to bind the GR sequence of interest for 
both the BclI and the N363S polymorphisms with specificity (Figure 9). 
Figure 9. Upstream and downstream primer sequences used for the 
BclI and the N363S SNPs. 
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The PCR reactions were run in a Bio Rad C1000 Thermal Cycler©. The conditions are 
shown in Table 3. 
 
Gel Electrophoresis 
PCR reactions were electrophoresed on a 2% agarose gel at 100 V for 
approximatively 10 minutes. The use of ethidium bromide permitted the visualization of 
the bands under UV light, and provided a method for genotyping patients. 
Data Collection 
Metabolic data was obtained from each patient’s medical records kept in Ellis 
Hospital’s electronic database. The data collected consisted of height, fasting blood 
glucose, serum triglycerides, LDL cholesterol, HDL cholesterol, systolic and diastolic 
BP, surgery type and date, original weight with date, pre-surgery weight with date, lowest 
weight with date, and current weight with date. 
Table 3. PCR Conditions for both SNPs.  
 BclI N363S 
Denaturation Temperature 95°C 95°C 
Primer Annealing 
Temperature 
56°C 55°C 
Primer Extension 
Temperature 
72°C 72°C 
Number of Cycles 36 36 
15 
 
Data Analysis and Statistical Testing 
One-way ANOVAs using IBM SPSS Statistics© were used to evaluate the 
relationship between genotype and BMI, fasting blood glucose, serum triglycerides, LDL 
cholesterol, HDL cholesterol, and systolic and diastolic BP. A significance criterion p < 
0.05 was used. We also observed the relationship between genotype and success of 
bariatric surgery as measured by %EBWL.   
16 
 
RESULTS 
Genotyping was performed as described in materials and methods. Section E of 
the Appendix shows the agarose gel electrophoresis of the PCR reactions. A complete 
accounting of individual genotype assignments and other clinical information - where 
available - can be found in Section F of the Appendix for the bariatric patients and 
Section G for the undergraduate students. 
Prevalence of the SNPs 
From the genotyping results, we were able to compare the prevalence of the BclI 
and N363S SNPs in both the study population and the control population (Appendix, 
Section H). The prevalence of both SNPs was higher in the obese population than in the 
normal weight population. 
Association between SNPs and Metabolic Parameters 
One-way two-tailed ANOVAs using a p<0.05 significance criterion were 
performed using IBM SPSS© to look for differences in the bariatric patients’ metabolic 
profiles based on their genotype for the BclI SNP (Appendix, Section I). Homozygous 
MUTs for the BclI SNP were only significantly different from heterozygotes and 
homozygous WTs in serum triglyceride levels; they had higher levels of triglycerides 
than the other groups (p<0.05). All other associations were non-significant. However, 
homozygous MTs tended to have higher LDL cholesterol levels, slightly higher BMIs, 
and lower HDL cholesterol levels (Appendix, Section J for BclI and Section K for 
N363S). 
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Only 1 participant tested positive for the N363S SNP, making statistical analyses 
impossible. This patient was heterozygous for the N363S SNP and heterozygous for the 
BclI SNP. When compared to BclI-positive/N363S-negative participants, this patient 
tended to have higher blood glucose levels, LDL cholesterol levels, and systolic BP 
(Appendix, Section L). 
Association between SNPs and Bariatric Surgery 
The participants’ %EBWL following bariatric surgery was organized based on the 
surgery they underwent and their BclI genotype (Appendix, Section M). For both the 
Roux-en-Y gastric bypass and the vertical sleeve gastrectomy, there was no difference in 
the average %EBWL between genotypes. However, for patients who underwent the 
gastric band, both heterozygotes and homozygous mutants tended to have a lower 
%EBWL than homozygous wild types. In addition, the BclI/N363S double heterozygote, 
who underwent a Roux-en-Y gastric bypass, tended to have a lower %EBWL than BclI-
positive/N363S-negative patients.   
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DISCUSSION 
In the present study, we hypothesized that 1) the prevalence of the BclI and 
N363S SNPs would be higher in an obese population than in a normal weight population, 
2) the presence of the SNPs would be significantly associated with poorer metabolic 
profiles, and 3) the presence of the SNPs would be associated with less success of 
bariatric surgery.  
Prevalence of the SNPs 
The results obtained in this study suggest that there is a difference in the 
prevalence of both the BclI and the N363S SNPs in obese populations compared to 
normal weight populations. This supports the theory that SNPs may be involved in the 
development of obesity. Many studies have looked at the prevalence of the SNPs in either 
obese or normal weight populations. A study by Gergics et al. (2006) found that the 
prevalence of the BclI SNP was 34.4% in a normal weight population, supporting our 
findings24. However, interestingly, Di Blasio et al. (2003) obtained a lower value, 27%, in 
their obese population25. This may be a direct consequence of the different populations 
that both studies used, highlighting the importance of characterizing the prevalence of the 
SNPs for different populations based on age, sex and ethnicity, among others. While we 
found no participant with the N363S SNP in our normal weight population, 0.9% of the 
normal weight population recruited by Di Blasio et al. (2003) were positive for the 
SNP25. Finally, Dobson et al. (2001) found that the prevalence of the N363S SNP was at 
3% in their obese population, and Di Blasio et al. (2003) reported it to be at 2.3%, both 
measurements being slightly higher than the value we found in our population25,26. 
Overall, our results agree to some extent with previous studies on the topic, and suggest 
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that the prevalence of the SNPs in obese populations is higher than in normal populations 
and thus, may in fact contribute to weight gain. 
Association between SNPs and Metabolic Parameters 
The main assumption of our study was that the MS may be a Cushingoid-like 
state characterized by hypersensitivity of the GR. In other words, the presence of 
glucocorticoid hypersensitivity may contribute to more morbid obesity phenotypes. By 
looking for associations between the presence of the SNPs and metabolic parameters 
characteristic of the MS, we hoped to provide support for the claim that glucocorticoid 
hypersensitivity may be the biological mechanism driving the MS. The results of 
previous studies have been mixed on the topic, but none to my knowledge have found a 
significant difference in serum triglycerides between BclI-positive and BclI-negative 
individuals. Some, however, have found associations with BMI, waist circumference and 
visceral adiposity11. 
The one major conclusion that can be taken from our findings and from multiple 
previous studies on the topic is that there is an enormous amount of variability in the 
phenotypic representation of SNP-positive individuals. Whether this is due to misguided 
attempts to make holistic generalizations from results obtained in drastically different 
populations, whether it can be ascribed to an overly narrow focus on SNPs of the GR, or 
even whether it can be attributed to the large amount of functional diversity of the GR, 
understanding why such inter-study or inter-population variability occurs remains an 
important goal to understand the role of SNPs in disease and obesity. To achieve that 
goal, it is essential that the structural effect of the BclI and N363S SNPs on the GR be 
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investigated further, so that the functional impact of the mutated GR protein be 
elucidated. 
One strategy is to look at the effect of multiple SNPs on phenotype. Comparing 
our only Bcl-positive/N363S-positive participant, who was heterozygous for both SNPs, 
to homozygous MUT for the BclI, we found some evidence that looking at the effect of 
multiple SNPs may be a valuable strategy. Our double heterozygote seemed to have 
higher blood glucose, LDL cholesterol and systolic BP, while being similar for all other 
parameters. This is in accord with Di Blasio et al (2003)’s findings that BclI-
positive/N363S-positive individuals have significantly higher LDL and total cholesterol, 
and tend to have higher systolic and diastolic BP25. It remains to be confirmed whether 
blood glucose is also elevated in those individuals.  
A further strategy, which has been termed “haplotype analysis”, is to look at 
contributions from all hypersensitivity-causing and resistance-causing SNPs in the GR 
gene on a patient’s phenotype. A recent study by Yan et al. (2014) has looked at the 
combined effect of 4 different SNPs on metabolic parameters characteristic of the MS5. 
Overall, as expected, the researchers found that presence of hypersensitivity-causing 
SNPs with an absence of resistance-causing SNPs correlated with MS-like phenotypes, 
while the presence of resistance-causing SNPs with an absence of hypersensitivity-
causing SNPs were associated with favorable metabolic profiles. However, depending on 
the combination of the SNPs present in an individual’s genome, there were instances 
where resistance-causing SNPs appeared to mediate the effects of hypersensitivity-
causing polymorphisms, suggesting that it may be important to look at the effect of all 
SNPs, hypersensitivity-causing and resistance-causing, on phenotype.  
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Finally, some studies suggest that other abnormalities in an individual’s HPA 
pathway may be responsible for metabolic deficiencies. One likely candidate based on 
other studies, 11β-HSD 1, which has been shown to have different expression and 
activation patterns in the liver and adipose tissues, has been linked to the development of 
central obesity27,28. In addition, SNPs in the gene encoding the enzyme have been found 
to cause metabolic abnormalities29,30. All in all, a full understanding of the role of the 
HPA axis in the development of obesity and the MS may necessitate a combined 
investigation of multiple genes involved in important regulatory steps of this pathway.  
Association between SNPs and Bariatric Surgery 
In recent years, bariatric surgery has emerged as the best treatment option for 
obesity. However, for reasons still unknown, its success varies across individuals. 
Because of the invasiveness of the surgery, an important goal of researchers in the field 
has been to find ways to predict the success of surgery. Still et al (2014) identified a set a 
preoperative variables such baseline BMI, initial weight loss and iron deficiency that 
have been shown to be helpful in predicting the success of bariatric surgery31. In 2011, 
the same group found four SNPs in different obesity-related genes that were associated 
with poorer weight loss outcomes following gastric bypass surgery32. There is thus some 
evidence that an individual’s genetic makeup may play a role in his ability to lose weight 
after bariatric surgery. This has prompted a recent large study by Seip et al. (2016) that 
grouped successful and unsuccessful patients based on BMI drop pre and post gastric 
band and gastric bypass surgeries, respectively, and compared the prevalence of a large 
amount of SNPs in these groups23. They found no differences in the allele frequency of 
GR SNPs between successful and unsuccessful patients who underwent a gastric bypass. 
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However, interestingly, they found a SNP in intron 2 of the GR gene, a location near the 
BclI SNP, which was present in significantly higher proportion in the unsuccessful 
gastric band group. This polymorphism has yet to be identified as hypersensitivity-
causing or resistance-causing, but these results suggest that it may be hypersensitivity-
causing. As a whole, this research supports our findings for an association between the 
presence of the BclI and poorer weight loss outcomes following gastric band surgery. 
More research is required to establish whether these loci may represent important data for 
predicting favorable outcomes of bariatric surgery.  
In any case, the relationship between GR SNPs and gastric band surgery requires 
further investigation. It remains unclear as to why SNPs of the GR affect weight loss in 
patients who undergo a gastric band, but not in patients who undergo a gastric bypass, or 
based on our findings, a gastric sleeve. One possibility is that the hormonal changes 
associated with the gastric bypass and gastric sleeve surgeries may mitigate the negative 
effects of the GR SNPs on weight homeostasis. A study by Korner et al. (2009) found 
that individuals who had undergone a gastric bypass had a higher GLP-1 response and 
lower ghrelin, leptin, fasting blood glucose and insulin levels than individuals who got 
the gastric band surgery33. There is thus a clear difference in the hormonal impact of 
more invasive surgeries such as the gastric bypass or sleeve, compared to less invasive 
surgeries such as the gastric band. Whether and how these endocrine changes mediate GR 
SNPs’ effects on metabolism is yet unknown, but this could help understand one of the 
many ways bariatric surgery has such drastic impact on weight homeostasis.  
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Clinical Significance 
The present findings also have important clinical implications. It remains possible 
that the MS is caused by hypersensitivity of the GR. However, our findings suggest that 
inclusion of many SNPs or even better, an individual’s haplotype, may be better 
predictors of obesity phenotypes and thus, may be responsible for the MS and for its 
variability in symptomatic presentation.  
As for the GR SNPs’ impact on the success of bariatric surgery, it seems that 
particular attention must be paid to individual’s undergoing the gastric band. The gastric 
band may not be the best options for patients who have GR hypersensitivity-causing 
SNPs. Alternatively, patients who test positive for these SNPs and who prefer the gastric 
band for alternative reasons, may have to be kept on a GR-blocker such as RU-486 - 
clinically known as Korlym - following their surgery. Taken together, these results 
highlight the potential of full-genome sequencing in the treatment of obesity, and in 
improving the success of bariatric surgery. 
Limitations 
In order to understand the implications of this study, it is important to note some 
limitations. Firstly, we were not able to obtain the patients’ waist circumference, which is 
the criterion used to diagnose the MS because it is more representative of an individual’s 
central adiposity. Secondly, a larger sample size would have been necessary to better 
establish the significance of our results. Thirdly, our sample consisted mostly of 
Caucasians, and to some extent, of individuals with a history of post-surgical 
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complications, and thus, one should be careful when generalizing to the whole obese 
population. 
Conclusion 
All in all, obesity is an extremely complex multi-causal phenomenon, and 
undoubtedly, more research will be necessary to truly understand the role of the HPA 
axis and of the GR in fat accumulation.  However, the present study provides evidence 
for the impact of genetics in the development of the obesity, more precisely the MS, and 
in the recovery of patients following bariatric surgery. Our hope is that these findings 
may guide clinicians’ interventions to slow the progress of obesity, and help obese 
patients improve their quality of life.  
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APPENDIX 
Section A – Ellis Hospital IRB Approval 
 
1101 Nott Street    Schenectady, New York 
12308   
Phone: (518) 243-4011    
www.ellismedicine.org 
 
December 23, 2014 
Anne Jones RN 
Brian D Cohen PhD 
Ellis Medicine Bariatric Care Center 
2125 River Road Suite #302 
Niskayuna, NY 12309 
 
Re:  Prevalence of Glucocorticoid Receptor Polymorphisms in Morbidly Obese Patients 
 
Dear Ann and Dr. Cohen 
Thank you for attending the December 18, 2014 meeting of the Institutional Review 
Board. Under full board review the protocol, informed consent (with changes) and other 
materials presented for the above mentioned study were approved.  The study was 
approved for 2 years with an interim report due at the June 2015 IRB meeting.  As a 
reminder, no additional changes may be made to this project without first submitting the 
changes to the IRB for review.  Any inquiries or unanticipated problems must also be 
promptly reported. 
Thank you for your continued interest in medical research. 
Sincerely, 
 
Michael V. Pasquarella 
Michael V. Pasquarella Pharm.D., R.Ph. 
Chairperson 
Institutional Review Board 
 
cc: Pat Biggica
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Section B –  Union College Human Subjects Review Committee Approval 
Greetings, 
 
The project/s listed below is/are granted conditional approval by the acting chair of the Union 
College Human Subjects Review Committee.  Please make the following changes: 
 
1.  Please change third paragraph of informed consent to read "... your name with your DNA 
material, your height, or your weight" 
 
2.  Please state the DNA material will be destroyed after use (and ensure that this is indeed done) 
 
3.  Ensure that the instructor is not aware (and will not be made aware) of which students opted to 
participate and which did not.  Ensure that students understand that the instructor will not know 
of students' participation or lack thereof. 
 
If these changes are amenable, please send a note to me stating that you have made them (and, in 
the case of #3, how).   
  
Please keep in mind: 
1.  Any changes to the proposal must be reviewed before implementation.  
2.  The approval for this study expires one year from the approval date presented below. 
  
George Bizer 
Acting Chair, Union College HSRC 
 
15070 29-Sep-15 Gingras, Sebastien Cohen, B BIO Prevalence of 
Glucocorticoid Polymorphisms in an Undergraduate Population Conditional per 9/29 email 
 
- - - - - - - - - - - - - - - - - - - - - - - - - - - - 
George Y Bizer, PhD 
Professor and Chair of Psychology 
Union College, Schenectady, NY 
- - - - - - - - - - - - - - - - - - - - - - - - - - - - 
georgebizer.com        518-388-6228 
- - - - - - - - - - - - - - - - - - - - - - - - - - - -  
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Section C - Participant Informed Consent Form 
Informed Consent Form 
 
The purpose of this research project is to look for a correlation between polymorphisms of the 
glucocorticoid receptor (variations in the DNA sequence of the natural receptor for the hormone 
cortisol) and clinical manifestations of obesity and related comorbidities such as elevated blood 
sugar, blood pressure, increased waist/hip circumference ratio, and altered serum lipid profiles.   
Agreeing to participate in this study means that you will allow the testing of your DNA for the 
purposes of identifying receptor variations and you are agreeing for relevant medical data to be 
provided to the researchers to compare with the receptor variations. You will not receive 
information about your individual results from this study.  Your DNA will not be used for any 
other purpose or analyzed in any other way.  After 2 years, your DNA sample will be destroyed. 
Your decision about whether or not to participate will not affect your treatment by Ellis Bariatric 
Medicine.  You will not be compensated for your participation in the study. 
If you decide to participate you will be asked to perform a mouthwash with sterile saline that will 
allow us to recover cells from inside your cheek.  Some people find the salty taste of the saline 
wash a little unpleasant but should provide no significant discomfort or risk for you.  
Identification of which genetic variant(s) of this gene you have will not affect your treatment in 
any way.  As information is gathered about the relationship between variations of the cortisol 
receptor gene and obesity (and related diseases), it may eventually help identify opportunities for 
complimentary therapies for obesity, but this is beyond the scope of the present study.  Currently 
we are strictly interested in determining if there is a connection between this gene and obesity 
(and related diseases) and any discovery will not affect your treatment plan. 
Your DNA sample will be coded with your patient identification number instead of your name 
before it is given to researchers at Union College for DNA analysis.  The researchers will also be 
given access anonymously to relevant medical information from your records required to 
complete the study.  Records given to Union College researchers will only have your patient ID 
number and not your name.  Relevant medical information will include but not strictly be limited 
to: 
1. Your weight before you began treatment 
2. Your height 
3. Your waist to hip ratio or waist circumference (where available) before you began 
treatment 
4. Fasting blood sugar 
5. Serum triglycerides 
6. Serum LDL and HDL 
7. Blood pressure 
8. Related medications that you are taking that might affect these measures 
9. Treatments you receive at Ellis Bariatric such as medications and surgical procedures 
 
Your DNA sample will be kept in the laboratory of Dr. Brian Cohen at Union College and will 
only be accessible to him or to his student researchers working on this research project. Similarly, 
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relevant medical information made available to Dr. Cohen will only be available to him or his 
student researchers and will not be accessible to anyone else at Union College.   
Although we do not anticipate making any discoveries that would alter your care or cause you to 
wish to drop out of the study, if any such discoveries are made the medical staff of Ellis Bariatric 
will contact you and give you the option to withdraw from the study.  Choosing to withdraw from 
the study will in no way affect your care as a patient of Ellis Bariatric.  We anticipate that more 
than 100 patients will be a part of the study and the more patients that are included, the more 
significant any findings will be.   
If you have any questions, please ask Anne Jones, RN, CBN, at Ellis Bariatric or Dr. Brian 
Cohen, Union College. Their contact information can be found below.  You will be asked to sign 
one copy of this informed consent form and will be given a copy to keep for your records. 
The choice to be in this study and to stay in this study is strictly voluntary.  Refusal to participate 
will involve no penalty or loss of benefits which you are otherwise entitled. You may discontinue 
your participation at any time with no penalty or loss of benefits which you are otherwise 
entitled.  If you wish to leave the study, please contact  Ms. Anne Jones and inform her that you 
wish to withdraw from the study.  You will be asked to sign a written form indicating your desire 
to withdraw. Ellis Bariatric will then inform Dr. Cohen of your ID number and your DNA sample 
will be destroyed and your relevant medical information will be removed from the data set. 
Thank you for considering being a part of this research study.  If you have any questions before 
participating or at any time during the study, please do not hesitate to contact us 518-243- 
Anne Jones, RN, CBN 
Ellis Bariatric 
Medicine 
jonesa@ellismedicine.
org 
518-831-7030 
 
Brian D. Cohen, PhD 
Union College 
cohenb@union.edu 
518-388-8018 
 
Michael Pasquarella, PharmD, 
RPh 
Chair, Institutional Review 
Board 
Ellis Hospital 
pasquarellam@ellismedicine.org
1. I understand that I will not receive the results from the testing.  
2. I have been informed as to who may have access to my biological sample, and that 
the laboratory may retain any leftover sample until the end of the study, at which 
point it will be destroyed.  
3. I have read the material provided and this consent form in full. My questions have 
been answered to my satisfaction.  
4. I consent to provide a sample for genetic testing and to have relevant medical data 
provided anonymously to the researchers.  
5. I understand that my participation is completely voluntary and I may withdraw at any 
time without affecting my care as a patient of Ellis Bariatric. 
  
___________________________________________________________________________ 
Signature                                                                     Date  
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D – DNA Extraction Protocol 
Isolation of Crude Human Genomic DNA samples suitable for PCR   
 
 The source of DNA that you will use for PCR reactions next week will be your 
cheek cells, which will be obtained by a sterile saline mouthwash.  The cells are collected 
by centrifugation and resuspend in a solution containing the resin "Chelex", which binds 
metal ions that would otherwise inhibit the PCR reaction.  The cells are then lysed by 
boiling, and centrifuged to remove cell debris and the Chelex resin. The result is a crude 
genomic DNA prep that is "good" enough for PCR!  
 
You should have the following materials available before you start: 
 
Materials: 
 
Microfuge tubes and racks; micropipettors and tips  
One 15 ml plastic “Blue-top” tube 
One Non-sterile (but unused) plastic “Dixie” cup 
One plastic transfer pipette  
Labelled Waste container for “spit” waste 
Microfuge tube containing 1.2 ml of 10% Chelex (labeled  “Chelex")  
  
Shared Materials: 
 
Clinical Table-top Centrifuge for pelleting cells 
Boiling water baths with “floatie” for boiling samples 
Microfuge 
 
1)  Get a boiling water bath ready for use in step 8.  Fill up an ice bucket halfway using 
crushed ice obtained from the Biology “autoclave room” on the third floor.   
 
2)  Label a 15 ml tube (blue-top) with your initials on the top and the side of the tube, and 
pipette (or carefully pour) 10 ml of sterile saline into the tube. Label a new microfuge 
tube with your initials, also on the top and side of the tube. 
 
3)  Pour all of the saline solution into your mouth (don't swallow it!), and vigorously 
swish for 15 seconds.  Carefully expel the fluid into a plastic Dixie cup, and then pour the 
liquid back into the 15 ml tube and reclose the cap. 
 
4)  Place your tube in a clinical centrifuge balanced against another tube opposite it in the 
rotor.  Try and fill up the rotor if you can with tubes from other members of the class.  
Centrifuge for 10 minutes at 1,000 X g for 10 minutes to pellet the cells. 
 
5)  After the spin is over, use a transfer pipette to pipette off as much of the supernatant 
as possible into the labeled waste container (we'll autoclave this later).  Pipette off the 
liquid so that the cells remain with only a minimal amount of liquid (approx 200 µL).  
You might have to briefly (1 min.) spin the tube again if the cells get dislodged from the 
side/bottom of the tube during this process.  Resuspend the cells in the minimal volume 
of remaining supernatant by vortexing, and then transfer the whole volume using the 
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same plastic transfer pipette to a new, labelled microfuge tube. Vortex this tube 
containing the cells for 5-10 seconds, making sure that there are no clumps of cells 
remaining.  
 
6)  Resuspend the Chelex beads (in the microfuge tube labeled "10% Chelex") by 
vortexing for 10 seconds.  Before the beads have had a chance to settle, pipette 500 µL of 
Chelex solution into your microfuge tube containing the cells.   
 
7)  Resuspend the cells in the Chelex by vortexing for 10 seconds. Make sure that no cell 
clumps remain.  
 
8)  Incubate the microfuge tube containing the cells/Chelex mixture in the boiling water 
bath for 10 minutes, using a plastic "floatie".  Other peoples' tubes will also be boiled at 
the same time in the water bath, so make sure that your tube is labelled well! 
 
9)  Remove the floatie carefully from the boiling water bath, take your tube and incubate 
it on ice for two minutes.  Spin the tube in a microfuge (max. speed) for 1 minute to 
pellet the Chelex and cell debris to the bottom of the tube. 
 
10)  Using a 200 µL pipette, carefully transfer 200 µL of the supernatant (pipette from 
the top) to a new, labeled (with your initials) microfuge tube.  Avoid transferring any of 
the pelleted cells or the Chelex. Discard the tube containing the pellet. YOUR PREP IS 
DONE AT THIS POINT! You should store your genomic DNA in the fridge in a labeled 
box or tube rack.
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Section E – Examples of Agarose Gels for both the BclI and the N363S SNPs 
 
BclI 
N363S 
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Section F – Bariatric Patients’ Metabolic Data and Genotypes 
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Section G – Undergraduate Students’ Metabolic Data and Genotypes 
Student Number Weight Height BclI Genotype N363S Genotype 
M1 170 65 wt 
 
M2 110 64 hetero 
 
M3 140 70 hetero wt 
M4 125 62 hetero wt 
M5 152 64 wt 
 
M6 145 66 hetero wt 
M7 106 60 hetero 
 
M8 100 64 
  
M9 135 71 hetero wt 
M10 189 70 wt wt 
M11 135 72 hetero wt 
M12 130 71 wt wt 
M13 190 68 
  
T1 182 70 wt 
 
T2 115 59 wt 
 
T3 150 63 
  
T5 160 70 wt wt 
T6 115 62 wt 
 
T7 141 66 hetero wt 
T8 145 71 hetero 
 
T9 162 73 wt 
 
T10 130 65 wt wt 
T11 110 66 
  
T15 210 73 wt wt 
W1 195 73 hetero wt 
W2 180 72 hetero wt 
W3 178 71 wt wt 
W4 104 62 wt wt 
W5 112 63 
  
W6 140 71 mut wt 
W7 128 64 mut wt 
W8 150 68 hetero wt 
W9 
  
wt wt 
W10 180 72 hetero wt 
W11 
  
hetero wt 
W13 190 72 wt wt 
W14 265 70.5 
  
40 
 
Th1 152 55 hetero wt 
Th2 160 62 hetero wt 
Th3 160 67 
 
wt 
Th4 135 63 mut wt 
Th5 114 61 mut 
 
Th6 130 60 
 
wt 
Th7 185 72 hetero 
 
Th8 139 64 wt wt 
Th9 185 70 
  
Th10 117 59 
 
wt 
Th12a 130 66 
 
wt 
Th12b 140 65 
 
wt 
Th13 155 64 
  
Th14 165 73 
 
wt 
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Section H – Prevalence of BclI and N363S SNPs 
 
Prevalence of BclI and N363S Single-Nucleotide Polymorphisms (SNPs) 
  BclI N363S 
 Percentage N Percentage N 
Prevalence in normal weight 
population 
33.78% 37 0% 32 
Prevalence in obese population 42.71% 48 1.72% 29 
      
 
  
42 
 
Section I – Results of one-way ANOVA 
 
Results of one-way ANOVAs comparing homozygous mutants and heterozygotes 
Metabolic Parameters Significance 
BMI p = 0.575 
Glucose p = 0.989 
Triglycerides   p = 0.016* 
LDL p = 0.510 
HDL p = 0.824 
Systolic BP p = 0.569 
Diastolic BP p = 0.623 
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Section J – BclI Graphs 
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Section K– N363S Graphs 
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Section L – Association of SNPs and Double Heterozygosity with Metabolic 
Parameters 
 
  
Association of SNPs and Double Heterozygosity with Metabolic Parameters (* p<0.05 compared to WT) 
 Alleles BclI BclI/N363S 
Genotype WT Hetero MT Hetero/Hetero 
Metabolic Parameters 
Average  
(+/-se) 
Average  
(+/-se) 
Average  
(+/-se) 
 BMI 47.63 (2.09) 45.14 (1.15) 48.26 (3.55) 49.08 
Glucose 105.67 (6.66) 99.67 (10.95) 97.20 (9.00) 127  
Triglycerides 
154.80 
(21.97) 
117.47 
(20.82) 
249.60 
(56.06)* 135 
LDL 104.80 (8.01) 102.13 (6.34) 
116.60 
(11.56) 159  
HDL 56.30 (5.44) 52.27 (3.55) 47.80 (4.35) 53  
Systolic BP 126.82 (4.36) 125.31 (3.35) 117.60 (8.70) 140 
Diastolic BP 77.18 (1.10) 80.19 (1.81) 77.20 (3.20) 80  
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Section M – Percent excess weight loss following bariatric surgery by surgery type 
and genotype 
 
Percent excess weight loss following bariatric surgery by surgery type and genotype 
  Gastric band 
Roux-en-Y Gastric 
Bypass 
Vertical Sleeve 
Gastrectomy 
Alleles Genotype 
BclI 
WT 61% (16%) 73% (12%) 56% (8%) 
Hetero 34% (13%) 61% (8%) 65% (9%) 
MT 27% 61% (14%) 50% (10%) 
BclI/ 
N363S 
Hetero/ 
Hetero  
31% 
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